Market News & Trends
Nektar Therapeutics Moving 30 Research Jobs
Nektar Therapeutics recently announced it is consolidating its US-based research scientists at the company's existing San Francisco state-of-the-art R&D center, which is located adjacent to…
Particle Sciences & Pernix Therapeutics Enter Development Agreement
Particle Sciences, Inc. recently announced it is developing with Pernix Therapeutics a new topical dermatology product for the pediatric market. "There are multiple treatments for…
3/27/2012
Marinomed's Nasal Spray Achieves Positive Clinical Results Marinomed Biotechnologie GmbH, recently announced that data from a clinical trial for the company's iota-carrageenan nasal spray was…
Bend Research Launches New Biotherapeutics Development Initiative
Bend Research Inc. recently announced an initiative to expand its scientific and engineering expertise into biotherapeutics, including offering new technologies and equipment proven to improve…
Bioniche Life Sciences Secures $20 Million
Bioniche Life Sciences Inc. recently announced it has accepted an offer of a $20 million financing from investment funds managed by US-based Capital Royalty L.P.…
3/20/2012
Connell Brothers Signs Agreement With World's Top Chemical Company Connell Brothers Australasia recently announced it was appointed by BASF Australia, a subsidiary of BASF Corporation,…
Bend Research Technology Helps Advance Promising Compound
Bend Research Inc. recently announced a licensing agreement with Affinium Pharmaceuticals, Ltd in which Bend has licensed its proprietary spray-dried dispersion (SDD) technology to the…
Connell Brothers Signs Agreement With World's Top Chemical Company
Connell Brothers Australasia recently announced it was appointed by BASF Australia, a subsidiary of BASF Corporation, the world's leading chemical company, to distribute its human…
DSM & Agennix Sign Commercial Manufacturing Agreement
DSM Pharmaceutical Products and Agennix recently announced they have signed a new contract under which DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy (DCMI)…
Pion Launches Modern, High Throughput Complement to Conventional Franz Cells
Pion Inc. recently introduced the Skin PAMPA Test System, specifically designed to predict the permeability of drugs and dermal formulations through the human skin. The Skin…
ThromboGenics Enters Commercialization Agreement With Alcon
ThromboGenics NV recently announced it has entered into an agreement with Alcon (a division of Novartis), the global leader in eye care, for the commercialization…
Vascular Magnetics to Advance Magnetically Targeted Delivery System
Vascular Magnetics, Inc. recently announced it has raised $7 million in a Series A financing to advance the development of its proprietary, magnetically targeted drug…
Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics' Delivery Technology
Particle Sciences, Inc. (PSI) and Lyotropics Therapeutics, Inc. recently announced PSI has acquired the exclusive rights to the Lyotropics' LyoCell patent portfolio. The LyoCell technology allows…
Study Establishes XMetA as the First Allosteric Insulin Receptor-Activating Antibody to Improve Glycemic Control In Vivo
XOMA Corporation recently announced its study of XMetA, the company's fully human allosteric monoclonal antibody to the insulin receptor, is available online and will be…
3/13/2012
Aegerion Pharmaceuticals Submits US & EU Marketing Applications Aegerion Pharmaceuticals, Inc. recently announced it has submitted an NDA to the US FDA and an MAA…
Aegerion Pharmaceuticals Submits US & EU Marketing Applications
Aegerion Pharmaceuticals, Inc. recently announced it has submitted an NDA to the US FDA and an MAA to the EMA seeking approval of Aegerion's lead…
CiToxLAB Increases Inhalation Test Capabilities
CiToxLAB recently announced it has increased its inhalation test capabilities in North America and Europe. The demand for studies to assess the safety of pharmaceuticals…
Lipid Therapeutics Licenses European Rights to its Lead Product
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, recently announced they have entered into a…
Mersana Therapeutics Strikes $270 Million Antibody-Drug Conjugate Deal
Mersana Therapeutics, Inc. recently announced it has entered into a collaboration agreement with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology…
3/6/2012
Avanir & Concert Announce Exclusive License Agreement Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into an exclusive license agreement that…
